<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327509</url>
  </required_header>
  <id_info>
    <org_study_id>004-KAR-2004-001</org_study_id>
    <nct_id>NCT00327509</nct_id>
  </id_info>
  <brief_title>mRNA Expression in Lymphocytes of Glaucoma Patients</brief_title>
  <official_title>Messenger Ribonucleic Acid Expression in Lymphocytes of Glaucoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare messenger ribonucleic acid (mRNA) expression of various&#xD;
      genes in lymphocytes between glaucoma patients and sex and age-matched healthy subjects. A&#xD;
      secondary objective is to analyze the impact of different forms of glaucoma or of a&#xD;
      vasospastic propensity on the findings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is a leading cause of blindness world-wide. Chronic primary open-angle glaucoma is&#xD;
      the most common form among Caucasian patients. The glaucoma patients will be divided into&#xD;
      four groups: (1) high tension glaucoma, (2) normal tension glaucoma, (3) pseudoexfoliation&#xD;
      glaucoma, and (4) juvenile glaucoma. Healthy subjects are separated into two age groups.&#xD;
      Vasospastic propensity will be assessed with a questionnaire: patients and subjects answering&#xD;
      yes to the questions: &quot;do you have always cold hands, even during summer time?&quot; and &quot;do other&#xD;
      people tell you that you have cold hands?&quot; will be classified as vasospastic, and as normals&#xD;
      if they deny a history of cold hands. Blood will be drawn from an arm vein, lymphocytes will&#xD;
      be isolated and mRNA of following genes will be assessed in these lymphocytes:&#xD;
&#xD;
      Nuclear proteins: NF-kappa B, XPGC, P53, XIAP; Multi-drug resistance proteins: ABC 1, ABC 8,&#xD;
      MDR 3; Adhesion protein: ICAM 1; Blood brain barrier breakdown protein: P2Y; Energy&#xD;
      metabolism proteins: Adrenodoxin, Adrenodoxin-reductase, Cytochrome p450,&#xD;
      Cytochrome-reductase, Alcohol-dehydrogenase; Tissue remodeling proteins: MMP 9, MMP 8, MMP&#xD;
      14, TIMP 1, TIMP 2, TIMP 3, TIMP 4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Glaucoma</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1-HTG</arm_group_label>
    <description>high tension glaucoma highest IOP &gt; 21 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-NTG</arm_group_label>
    <description>normal tension glaucoma highest measured IOP &lt; 21 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-PEX</arm_group_label>
    <description>pseudoexfoliation glaucoma PEX material visible</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4-Juvenile</arm_group_label>
    <description>juvenile glaucoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-Control1</arm_group_label>
    <description>healthy subjects (age group 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6-Control2</arm_group_label>
    <description>healthy subjects (age group 2)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      white cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        glaucoma patients, healthy subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Glaucoma patients&#xD;
&#xD;
          -  diagnosis of chronic glaucoma with typical glaucomatous disc and visual field damage&#xD;
&#xD;
          -  a present or past diurnal tension curve with an average intraocular pressure above 21&#xD;
             mmHg without treatment HTG)&#xD;
&#xD;
          -  a present or past diurnal tension curve with an average intraocular pressure below 21&#xD;
             mmHg without treatment (NTG)&#xD;
&#xD;
          -  a present or past diurnal tension curve with an average intraocular pressure above 21&#xD;
             mmHg without treatment and signs of pseudoexfoliation in the anterior segment (PEX)&#xD;
&#xD;
          -  a juvenile-onset open-angle glaucoma with a present or past diurnal tension curve with&#xD;
             an average intraocular pressure above 21 mmHg without treatment (Juvenile Glaucoma)&#xD;
&#xD;
        Healthy subjects&#xD;
&#xD;
          -  no history of ocular disease&#xD;
&#xD;
          -  no history of systemic disease&#xD;
&#xD;
          -  no history of alcohol/drug abuse&#xD;
&#xD;
          -  normal blood pressure (100-140 / 60-90 mmHg)&#xD;
&#xD;
          -  best corrected visual acuity above 20/25 in both eyes&#xD;
&#xD;
          -  no pathological findings upon a slit-lamp examination and indirect fundoscopy&#xD;
&#xD;
          -  IOP &lt; 20 mmHg in both eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ametropia &gt; 3 dpt&#xD;
&#xD;
          -  Iridocorneal angle extremely narrow with complete or partial closure as determined by&#xD;
             gonioscopy&#xD;
&#xD;
          -  Pigmentary dispersion&#xD;
&#xD;
          -  any abnormality which in the physician's view would prevent reliable applanation&#xD;
             tonometry&#xD;
&#xD;
          -  History of chronic or recurrent severe inflammatory eye disease such as scleritis or&#xD;
             uveitis&#xD;
&#xD;
          -  History of ocular trauma or intraocular surgery within the past 6 months&#xD;
&#xD;
          -  History of infection or inflammation within the past 3 months&#xD;
&#xD;
          -  History of clinically significant or progressive retinal disease such as retinal&#xD;
             degeneration, diabetic retinopathy or retinal detachment&#xD;
&#xD;
          -  Need for any concomitant medications that may interfere with the evaluation of ocular&#xD;
             blood flow&#xD;
&#xD;
          -  significant history and/or active alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selim Org√ºl, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel, Eye Clinic</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>May 17, 2006</study_first_submitted>
  <study_first_submitted_qc>May 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2006</study_first_posted>
  <last_update_submitted>August 19, 2009</last_update_submitted>
  <last_update_submitted_qc>August 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Selim Orgul</name_title>
    <organization>University Hospital, Basel, Switzerland</organization>
  </responsible_party>
  <keyword>mRNA</keyword>
  <keyword>glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

